Innocan Pharma's Groundbreaking LPT-CBD for Dogs
Innocan Pharma Corporation is making substantial strides in the realm of veterinary medicine with its innovative LPT-CBD treatment. This pioneering approach aims to alleviate osteoarthritis pain in dogs, providing a new ray of hope for pet owners seeking effective solutions for their beloved companions.
Long-Term Pain Relief
The LPT-CBD treatment offers promising results from an extended compassionate therapy program designed specifically for dogs with naturally-occurring osteoarthritis. Reports indicate significant pain reduction and enhanced mobility following repeated liposomal-CBD injections. Notably, these positive outcomes last for several weeks post-injection, showcasing the treatment's potential in managing chronic pain.
Impressive Case Studies
Two canine patients, previously unresponsive to traditional treatments like NSAIDs and oral CBD, have shown remarkable improvements after receiving LPT-CBD. Their owners observed enhanced mobility and a noticeable uplift in overall well-being, supporting the assertion that LPT-CBD is an effective alternative for dogs suffering from chronic pain. One case has continued LPT-CBD treatment for 2.5 years, highlighting its long-lasting benefits.
Expert Opinions
Professor Chezy Barenholz, the Chief Scientific Officer at Innocan Pharma, expressed his enthusiasm for these results, stating, "The long-term effects of LPT-CBD provide substantial evidence for its viability as a treatment for chronic pain." This reflects Innocan's commitment to developing effective solutions not just for dogs, but potentially for human patients as well.
Advancing Veterinary Medicine
Dr. Eyal Kalo, the R&D Director at Innocan, emphasized the company's dedication toward obtaining FDA approval for LPT-CBD, aiming to set new standards in veterinary medicine and improve the quality of life for dogs suffering from chronic pain.
About Innocan Pharma
Innocan Pharma is at the forefront of the pharmaceutical and wellness industries. They have successfully developed a CBD-loaded liposome drug delivery system aimed at non-opioid pain management for patients. Alongside, they market a range of high-performance wellness products that promote a healthier lifestyle.
Future Developments in LPT-CBD
The strategic focus for Innocan includes conducting further studies and human trials for their LPT-CBD platform, suggesting a broader impact on healthcare. The goal is clear: to enhance the quality of life for both animals and humans through innovative approaches.
Frequently Asked Questions
What is LPT-CBD?
LPT-CBD is a liposomal-CBD injectable therapy developed by Innocan Pharma to relieve chronic pain in dogs suffering from osteoarthritis.
How does LPT-CBD differ from other treatments?
This treatment boasts unique attributes, including superior bioavailability and sustained pain relief effects that can last for several weeks post-injection.
What results have been reported from LPT-CBD trials?
Clinical observations indicate significant pain reduction and improved mobility in dogs treated with LPT-CBD after conventional treatments failed.
Is Innocan Pharma planning to expand its research?
Yes, Innocan is focusing on advancing LPT-CBD through additional studies and the pursuit of FDA approval for veterinary applications.
How can pet owners learn more about LPT-CBD?
Pet owners can visit Innocan Pharma's official website to find the latest updates and detailed information on their products and research.
